SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:gup.ub.gu.se/55571"
 

Sökning: onr:"swepub:oai:gup.ub.gu.se/55571" > Placebo-controlled ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004576naa a2200601 4500
001oai:gup.ub.gu.se/55571
003SwePub
008240528s2007 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:13889113
0247 a https://gup.ub.gu.se/publication/555712 URI
0247 a https://doi.org/10.1038/sj.npp.13012162 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:138891132 URI
040 a (SwePub)gud (SwePub)ki
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Landén, Mikael,d 1966u Karolinska Institutet4 aut0 (Swepub:gu)xlandt
2451 0a Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder.
264 c 2006-10-11
264 1b Springer Science and Business Media LLC,c 2007
520 a Serotonin reuptake inhibitors (SRIs) do not have to be administered continuously to be effective for premenstrual dysphoric disorder (PMDD), but can be given during luteal phases only. This is of practical importance, but also of theoretical interest since it suggests that the onset of action of SRIs is shorter in PMDD than in, for example depression. In this study, both continuous and intermittent SRI administration was compared with placebo, with the special purpose of analyzing if different PMDD symptoms respond differently depending on the treatment regimen. To this end, women meeting slightly modified DSM-IV criteria for PMDD (mean+/-SD age, 37+/-6.3 years) were treated for three menstrual cycles with paroxetine continuously, paroxetine during the luteal phase only, or placebo, the population completing at least one treatment cycle comprising 55-56 subjects per group. Continuous treatment with paroxetine reduced premenstrual symptoms effectively with a response rate of 85%. The effect size was highest for irritability (1.4) and lowest for lack of energy (0.5). Intermittent treatment was as effective as continuous treatment in reducing irritability, affect lability, and mood swings, but had a somewhat weaker effect on depressed mood and somatic symptoms. The study indicates that the response rate when treating PMDD with SRIs is high, and that irritability is a key target symptom. Symptoms such as irritability, affect lability, and mood swings appear to be more inclined to respond rapidly to SRIs, enabling intermittent treatment, than are, for example, the somatic symptoms.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Fysiologi0 (SwePub)301062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Physiology0 (SwePub)301062 hsv//eng
653 a Adult
653 a Disability Evaluation
653 a Double-Blind Method
653 a Drug Administration Schedule
653 a Female
653 a Humans
653 a Pain Measurement
653 a methods
653 a Paroxetine
653 a therapeutic use
653 a Placebos
653 a Premenstrual Syndrome
653 a drug therapy
653 a psychology
653 a Serotonin Uptake Inhibitors
653 a therapeutic use
653 a Treatment Outcome
7001 a Nissbrandt, Hans,d 1952u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology4 aut0 (Swepub:gu)xnisha
7001 a Allgulander, Christeru Karolinska Institutet4 aut
7001 a Sörvik, Karin4 aut
7001 a Ysander, Christina4 aut
7001 a Eriksson, Elias,d 1956u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi,Institute of Neuroscience and Physiology, Department of Pharmacology4 aut0 (Swepub:gu)xereli
7102 a Karolinska Institutetb Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi4 org
7730 t Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacologyd : Springer Science and Business Media LLCg 32:1, s. 153-61q 32:1<153-61x 0893-133X
7730 t Neuropsychopharmacologyd : Springer Science and Business Media LLCg 32:1, s. 153-61q 32:1<153-61x 1740-634X
8564 u https://www.nature.com/articles/1301216.pdf
8564 8u https://gup.ub.gu.se/publication/55571
8564 8u https://doi.org/10.1038/sj.npp.1301216
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:13889113

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy